Detalhe da pesquisa
1.
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
Clin Infect Dis
; 69(10): 1657-1664, 2019 10 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923816
2.
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
J Med Virol
; 90(1): 109-119, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28842997
3.
An interferon-free antiviral regimen for HCV after liver transplantation.
N Engl J Med
; 371(25): 2375-82, 2014 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25386767
4.
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
Antimicrob Agents Chemother
; 60(2): 1106-13, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26643326
5.
Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.
Hepatology
; 61(5): 1523-32, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25644279
6.
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.
Hepatology
; 62(4): 1037-46, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26147154
7.
In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.
Antimicrob Agents Chemother
; 59(2): 979-87, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25451055
8.
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Cardiovasc Drugs Ther
; 26(4): 349-58, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22622962
9.
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Cardiovasc Drugs Ther
; 25(1): 47-57, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21174145
10.
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
Cardiovasc Drugs Ther
; 25(1): 59-67, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21416219
11.
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Am Heart J
; 160(4): 759-66, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20934572
12.
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Am J Cardiovasc Drugs
; 10(3): 175-86, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20524719
13.
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Am J Cardiovasc Drugs
; 10(2): 73-84, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20136164
14.
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
Cardiovasc Drugs Ther
; 24(5-6): 421-8, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20953684
15.
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Clin Drug Investig
; 30(1): 51-61, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-19995098
16.
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
Am Heart J
; 157(1): 195-203, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19081418
17.
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Clin Drug Investig
; 28(10): 625-34, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18783301
18.
Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
Adv Ther
; 34(6): 1449-1465, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28536999
19.
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Clin Ther
; 35(8): 1186-98, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23891363
20.
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Am J Cardiovasc Drugs
; 12(2): 117-25, 2012 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22263674